Published in:
01-02-2011 | Erratum
Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock
Published in: Intensive Care Medicine | Issue 2/2011
Login to get accessExcerpt
Due to an oversight by the authors, incorrect data appeared in Table 2. The table is reproduced here with the corrected item in bold type.
Table 2
Serious bleeding rates in clinical trials of drotrecogin alfa (activated)
|
Study
|
Placebo n (%)
|
DAA n (%)
|
P
|
|---|---|---|---|
|
PROWESS
|
17 (2.0)
|
30 (3.5)
|
0.06
|
|
PROWESS (CNS)
|
1 (0.1)
|
2 (0.2)
|
NS
|
|
ADDRESS
|
28 (2.2)
|
51 (3.9)
|
0.01
|
|
ADDRESS (Day 0–6)
|
15 (1.2)
|
31 (2.4)
|
0.02
|
|
ADDRESS (CNS)
|
5 (0.4)
|
6 (0.5)
|
0.72
|
|
RESOLVE
|
16 (6.8)
|
16 (6.7)
|
0.97
|
|
RESOLVE (Day 0–6)
|
8 (3.4)
|
9 (3.8)
|
0.83
|
|
RESOLVE (CNS)
|
5 (2.1)
|
11 (4.6)
|
0.13
|
|
ENHANCE
|
–
|
155 (6.5)
|
–
|